The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.
Authors
Cheadle, Eleanor JSidon, Lauren
Dovedi, Simon J
Melis, M
Alduaij, Waleed
Illidge, Timothy M
Honeychurch, Jamie
Affiliation
Targeted Therapy Group, Paterson Institute for Cancer Research, Institute of Cancer Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.Issue Date
2013-06-18
Metadata
Show full item recordCitation
The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. 2013: Br J HaematolJournal
British Journal of HaematologyDOI
10.1111/bjh.12427PubMed ID
23772929Type
ArticleLanguage
enISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.12427
Scopus Count
Collections
Related articles
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
- Authors: Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA
- Issue date: 2011 Apr 28
- Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.
- Authors: Ai L, Ren H, Shi Y, Dong Y
- Issue date: 2008 Jun
- Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
- Authors: Singh V, Gupta D, Arora R, Tripathi RP, Almasan A, Macklis RM
- Issue date: 2014
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
- Authors: Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM
- Issue date: 2011 Apr 28
- γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
- Authors: Braza MS, Klein B, Fiol G, Rossi JF
- Issue date: 2011 Mar